Recently, Gene+ (Shaoxing) Technology Co., Ltd. unveiled the successful closure of its Series D funding round, amassing RMB 300 million. This round attracted prominent investors, such as the Shaoxing Yuecheng District Science and Technology Innovation and Talent Attraction Fund, alongside the Beijing Changping Industrial Development Investment Fund.

The capital raised in this financing endeavor is earmarked for the advancement of AI-driven multi-omics technologies, the augmentation of biomarker innovation pipelines, and the fortification of the global service network. Since its inception in 2015, Gene+ has dedicated its efforts to the precision medicine domain, constructing an AI-powered multi-omics platform and achieving notable breakthroughs across diverse areas.

Yang Ling, the President of Gene+, remarked that this funding round marks a pivotal achievement for the company. He emphasized that the newly acquired funds will be channeled into boosting R&D investments and expediting the transformation and deployment of core products. Investors exhibit a positive outlook on Gene+'s growth trajectory and are committed to bolstering its expanded footprint in the precision medicine sector. This support aims to facilitate the widespread adoption of relevant technologies and foster the progression of regional healthcare industries.